Literature DB >> 7916506

Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice.

S D Rencher1, K S Slobod, F S Smith, J L Hurwitz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916506     DOI: 10.1097/00007890-199409150-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  6 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression.

Authors:  Z Fu; M J Cannon
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 3.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients.

Authors:  K S Slobod; E Benaim; L Woodruff; S Nooner; J Houston; M Holladay; T Lockey; J L Hurwitz
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders.

Authors:  Stefanie Linnerbauer; Uta Behrends; Dinesh Adhikary; Klaus Witter; Georg W Bornkamm; Josef Mautner
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

6.  Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.

Authors:  J F Lacerda; M Ladanyi; D C Louie; J M Fernandez; E B Papadopoulos; R J O'Reilly
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.